Cadent Therapeutics Starts Phase I Trial with Essential Tremor Drug Candidate, Secures $40 Million to Advance Pipeline for Movement and Cognitive Disorders – CBI
Homepage/Press Release/Cadent Therapeutics Starts Phase I Trial with Essential Tremor Drug Candidate, Secures $40 Million to Advance Pipeline for Movement and Cognitive Disorders
Press Release
Cadent Therapeutics Starts Phase I Trial with Essential Tremor Drug Candidate, Secures $40 Million to Advance Pipeline for Movement and Cognitive Disorders